Looks like no one added any tags here yet for you.
This monoclonal antibody drug selectively targets TNF alpha
Humira® (Adalimumab)
This drug targets the complement system by binding to the C5 protein
Ultomiris® (Ravulizumab)
This oral, small molecule drug targets the complement system
Fabhalta® (Iptacopan)
This monoclonal antibody targets both TNF alpha and TNF beta
Enbrel® (Etanercept)
True or False. Entanercept (Enbrel®) is not effective in diseases such as Inflammatory Bowel Disease and sarcoidosis.
True
This drug inhibits IL-6 signaling and can cause liver function abnormalities
Actemra® (Tocilizumab)
This drug is a recombinant form of IL-1RA made in E. coli and is known to penetrate the CSF.
Kineret® (Anakinra)
A drug that acts as a decoy receptor and therefore can bind IL-1 beta as well as IL-1 alpha and IL-1RA
Arcalyst® (Rilonacept)
A drug specific for blocking IL-1 beta
Ilaris® (Canakinumab)
A drug that targets IL-23 and also IL-12
Stelara® (Ustekinumab)
A drug that neutralizes both IL-23 and IL-39
Tremfya® (Guselkumab)
This drug selectively inhibits IL-17A
Cosentyx® (Secukinumab)
This drug is a dual inhibitor of IL-17A and IL-17F
Bimzelx® (Bimekizumab)
This drug inhibits the actions of IL-17 family members that signal through IL-17RA
Siliq® (Brodalumab)
This drug neutralizes the activity of soluble BLyS (also known as BAFF)
Benlysta® (Belimumab)